Systemic Erythropoietin Injection in Patients Having Optic Atrophy
Systemic Erythropoietin Injection in Patients Having Optic Atrophy
The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.
The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Follow up after one month and three months by recording visual acuity and electro physiological studies.
Inclusion Criteria:
Exclusion Criteria: